Lost in Translation? Finding Our Way to Effective Alzheimer's Disease Therapies

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Efforts over the past two decades to develop effective disease-modifying treatments for Alzheimer's disease have been disappointing, while parallel efforts in another chronic neurologic disease, multiple sclerosis, have been remarkably productive. In an effort to advance development of therapeutics for Alzheimer's disease, these two fields are contrasted in terms of the utility of animal models, definition of study populations, and utility of biomarkers. Possible solutions are suggested, and the review concludes with description of some active peer-reviewed, publicly funded clinical studies which address some of the identified weaknesses in past clinical trials for age-related dementia.

Original languageEnglish (US)
Pages (from-to)S33-S39
JournalJournal of Alzheimer's Disease
Volume64
Issue numbers1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Alzheimer Disease
Nervous System Diseases
Multiple Sclerosis
Dementia
Chronic Disease
Animal Models
Biomarkers
Clinical Trials
Therapeutics
Population
Clinical Studies

Keywords

  • Alzheimer's disease
  • animal models
  • clinical trials

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Lost in Translation? Finding Our Way to Effective Alzheimer's Disease Therapies. / Quinn, Joseph.

In: Journal of Alzheimer's Disease, Vol. 64, No. s1, 01.01.2018, p. S33-S39.

Research output: Contribution to journalReview article

@article{2a7f367adaa24176a90cb38399aa8b6b,
title = "Lost in Translation? Finding Our Way to Effective Alzheimer's Disease Therapies",
abstract = "Efforts over the past two decades to develop effective disease-modifying treatments for Alzheimer's disease have been disappointing, while parallel efforts in another chronic neurologic disease, multiple sclerosis, have been remarkably productive. In an effort to advance development of therapeutics for Alzheimer's disease, these two fields are contrasted in terms of the utility of animal models, definition of study populations, and utility of biomarkers. Possible solutions are suggested, and the review concludes with description of some active peer-reviewed, publicly funded clinical studies which address some of the identified weaknesses in past clinical trials for age-related dementia.",
keywords = "Alzheimer's disease, animal models, clinical trials",
author = "Joseph Quinn",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-179930",
language = "English (US)",
volume = "64",
pages = "S33--S39",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "s1",

}

TY - JOUR

T1 - Lost in Translation? Finding Our Way to Effective Alzheimer's Disease Therapies

AU - Quinn, Joseph

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Efforts over the past two decades to develop effective disease-modifying treatments for Alzheimer's disease have been disappointing, while parallel efforts in another chronic neurologic disease, multiple sclerosis, have been remarkably productive. In an effort to advance development of therapeutics for Alzheimer's disease, these two fields are contrasted in terms of the utility of animal models, definition of study populations, and utility of biomarkers. Possible solutions are suggested, and the review concludes with description of some active peer-reviewed, publicly funded clinical studies which address some of the identified weaknesses in past clinical trials for age-related dementia.

AB - Efforts over the past two decades to develop effective disease-modifying treatments for Alzheimer's disease have been disappointing, while parallel efforts in another chronic neurologic disease, multiple sclerosis, have been remarkably productive. In an effort to advance development of therapeutics for Alzheimer's disease, these two fields are contrasted in terms of the utility of animal models, definition of study populations, and utility of biomarkers. Possible solutions are suggested, and the review concludes with description of some active peer-reviewed, publicly funded clinical studies which address some of the identified weaknesses in past clinical trials for age-related dementia.

KW - Alzheimer's disease

KW - animal models

KW - clinical trials

UR - http://www.scopus.com/inward/record.url?scp=85048635786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048635786&partnerID=8YFLogxK

U2 - 10.3233/JAD-179930

DO - 10.3233/JAD-179930

M3 - Review article

VL - 64

SP - S33-S39

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - s1

ER -